Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Investor Presentation (August 2021)
28 slides from Eris Lifesciences's investor presentation, Aug 3, 2021
Slide 1: Corporate Presentation filing letter to exchanges
Date: 3rd August, 2021 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: CORPORATE PRESENTATION Dear Sir/Madam, Pursuant to the requ
Slide 2: Eris Lifesciences Corporate Presentation July 2021
Eris Lifesciences Corporate Presentation July 2021
Slide 3: Business Highlights
Business Highlights Only Indian listed pharmaco with a pure-play 2021 22 Domestic Branded Formulations model Youngest among India’s Top-25 domestic 2017 branded formulation pharmacos Chronic and Sub-Chronic therapies account for 29 2012 91% of business 33 Focused portfolio with Top 15 Mother
Slide 4: Financial Snapshot
Financial Snapshot Revenues up 2x and PAT up 2.6x in last 5 years ₹ mn ₹ mn 12,119 4,306 Revenue PAT 12.8% 16.9% yoy Op Revenue yoy growth EBITDA growth 12,119 ₹ mn 5,970 ₹ 3,551 3,551 26.16 1,349 19.8% yoy 21.0% yoy FY16 FY21 PAT growth EPS growth Revenues up 6x and PAT up 17x in last 10 years 87 %
Slide 5: Track Record of Value-accretive Growth
Track Record of Value-accretive Growth Revenue (₹ mn) EBITDA (₹ mn) & % PAT (₹ mn) & % 5,000 3,551 12,119 4,306 80% 60% 70% CAGR 4,000 CAGR 3,000 CAGR 60% 15% 20% 21% 40% 3,000 50% 5,970 1,715 40% 2,000 1,349 2,000 30% 36% 1,000 29% 20% 20% 1,000 29% 23% 10% 0 0% 0 0% FY16 FY21 FY16 FY21 FY16 FY21 E
Slide 6: Chronic and Sub-Chronic Focus with Market-Leading Growth
Chronic and Sub-Chronic Focus with Market-Leading Growth An India-focused branded formulations business with 91% revenues Growth of Eris vs. the Indian Pharma Market (IPM) from Chronic and Sub-chronic therapies, primarily Oral Diabetes Care, Cardiac Care and VMN IPM Eris 10 of our Top-15 mother
Slide 7: Relentless Focus on Building Strong and Sustainable Brands
Relentless Focus on Building Strong and Sustainable Brands Our Top 15 Mother Brands contribute ~ 80% of our revenue High prescription ranks among super- specialists FY21 Sales (₹ mn) Market share 2,686 6% 1,445 4% Eris prescription ranks among leading doctor specialties* 1,338 8% 706 6% 646 7% #3 in
Slide 8: Continue to Create Value from Acquisitions
Continue to Create Value from Acquisitions Indian Branded Formulation Business of Strides Shasun (2017) Zomelis (2019) Discontinued tail-end brands; focused attention on Top-5 Consistently ranked #1 among all (83) Gx versions of brands in the portfolio (Renerve, Raricap, Ginkocer, Serlift Vildag
Slide 9: Three Pillars of Our Market Engagement
Three Pillars of Our Market Engagement The core focus of our market engagement is to enable clinicians to improve clinical outcomes in patients through timely and precision diagnosis and treatment 1 2 3 Dissemination of Generation of Patient Care and latest scientific actionable scientific support p
Slide 10: Leading the Digital Dissemination of Scientific Knowledge
1. Leading the Digital Dissemination of Scientific Knowledge • As a prominent stakeholder in the enhancement of scientific knowledge, Eris conducted ~2,500 interactions in FY21 covering 33,000+ doctors • Discussion topics included developments in the cardio-metabolic segment, impact of Covid on hear
Slide 11: Pioneering India-centric Studies to Generate Actionable Scientific Evidence
2. Pioneering India-centric Studies to Generate Actionable Scientific Evidence An ERIS An ERIS LIFESCIENCES initiative LIFESCIENCES initiative A landmark study covering 18,918 patients & 1,233 Doctors The First of its Kind study for Newly Detected Indian Diabetics across 355 Cities in 15 Indian stat
Slide 12: Patient Care – Driving Precision Diagnosis and Better Lifecycle Management
3. Patient Care – Driving Precision Diagnosis and Better Lifecycle Management Our Patient Care Initiatives (PCI) platform enables us to bring cutting- edge healthcare solutions to our patients through the involvement and Number of Patients Screened Number of Patients Screened Number of Patients Sc
Slide 13: Our Manufacturing Infrastructure
Our Manufacturing Infrastructure WHO-GMP manufacturing facility WHO GMP facility in Guwahati, Assam in Guwahati, Assam 74% of revenues from products 100,000 Built-up area (sq. ft) manufactured at Guwahati in FY21 345+ Products manufactured Capacity utilization for Prescription Products Capacity* Out
Slide 14: Pan-India Sales Presence and Distribution Network
Pan-India Sales Presence and Distribution Network Stockists Region-wise sales distribution (FY21) 11 Super Stockists 1 7 81 South , 38% 26 44 58 122 East, 10% 207 49 59 2 3 28 145 131 91 34 97 127 159 5 North , 22% West, 30% 101 165 2 Central Warehouses 1 23 Sales Depots 244 137 2,133 Stockists 5,00
Slide 15: Board of Directors
Board of Directors • Eight-member Board of Directors, comprising of four Executive Directors and four Independent Directors, including two women directors Amit Bakshi Krishnakumar V Inderjit Singh Negi Kaushal Shah Chairman and Executive Director & Executive Director Executive Director Managing Dire
Slide 16: Lifestyle Diseases Uptrend – A Large Market Opportunity for Eris
Lifestyle Diseases Uptrend – A Large Market Opportunity for Eris Expected prevalence of CVD in India Significant increase in prevalence of non-communicable diseases 69 (NCDs) in India; share of heart disease and metabolic disorders projected to expand in the years to come 29 22 19 India is calle
Slide 17: Enduring Pillars of Our Business Strategy
Hence the Enduring Pillars of Our Business Strategy CHRONIC AND SUB-CHRONIC THERAPIES 16
Slide 18: Key Growth Drivers (1/2)
Key Growth Drivers (1/2) Expansion of • Our business model of building strong and sustainable brands has enabled us to 1 power- maintain our growth trajectory during pandemic periods (Wave 1 as well as Wave brands’ 2) when MR-Doctor interactions were severely constrained franchise • There has been a
Slide 19: Key Growth Drivers (2/2)
Key Growth Drivers (2/2) Expansion of 3 • We plan to significantly expand our coverage of Specialists and Consulting physician coverage Physicians in the next 5 years Therapeutic • We are investing in diversification opportunities in high-growth areas like neurology, 4 diversification women’s health
Slide 20: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 21: Eris Lifesciences Ltd.
Eris Lifesciences Ltd. CORPORATE OFFICE: Commerce House, Near Shell Petrol Pump, 100 Feet Rd, Satelite, Prahlad Nagar, Ahmedabad, Gujarat 380015 CIN: L24232GJ2007PLC049867 Website : www.eris.co.in IR Contact Kruti Raval kruti@erislifesciences.com 20
Slide 22: Appendix
Appendix
Slide 23: Business Structure and Holdings
Business Structure and Holdings Eris Lifesciences Limited Promoters Aprica Healthcare Limited 9.7% Earlier known as UTH Public 54.1% Healthcare Limited 12.4% Kinedex Healthcare Private Limited FPI Eris Therapeutics Limited DIIs 23.8% Eris Healthcare Private Limited Promoter shares are unencumbered E
Slide 24: Financial Summary (1/2)
Financial Summary (1/2) P&L Summary FY17 FY18 FY19 FY20 FY21 Revenue 7,495 8,556 9,822 10,741 12,119 Gross Profit 6,449 7,215 8,285 9,025 9,736 Gross Profit Margin (%) 86.0% 84.3% 84.4% 84.0% 80.3% Operating EBITDA 2,691 3,220 3,449 3,684 4,306 Operating EBITDA Margin (%) 35.9% 37.6% 35.1% 34.3% 35.
Slide 25: Financial Summary (2/2)
Financial Summary (2/2) FY17 FY18 FY19 FY20 FY21 BS Summary Mar'17 Mar'18 Mar'19 Mar'20 Mar'21 Margin (%) Share Capital 138 138 138 136 136 Gross Margin 86.0% 84.3% 84.4% 84.0% 80.3% Reserves 5,534 8,476 11,368 12,828 15,628 EBITDA Margin 35.9% 37.6% 35.1% 34.3% 35.5% Shareholders Fund 5,672 8,614 1
Slide 26: Key Brands in Oral Diabetes Care and VMN therapies
Key Brands in Oral Diabetes Care and VMN therapies Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer Coupled with continued outperformance in key therapies as generation fast-growing molecules compared to the market Sulfonylurea rank 6 in the ~4,500 cr Glimepi
Slide 27: Key Brands in Cardiovascular Therapy
Key Brands in Cardiovascular Therapy High rank in Anti-Hypertensives: the fastest growing and largest segment of Cardiac Care Coupled with continued outperformance in key therapies as compared to the market rank 5 in the ~3,500 cr Telmisartan and combinations market CAGR over F11-FY21 Eritel CH rank
Slide 28: Thank You
Eris THANK YOU Eris Lifesciences
Eris Lifesciences — Investor Presentation (August 2021) on 6ix